Previous 10 | Next 10 |
Today, we revisit a small oncology concern from across the pond named NuCana. The company continues to advance a pipeline of improved versions of widely-prescribed chemotherapy agents. A full analysis follows in the paragraphs below. For further details see: Circling Bac...
EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in the following conferences: Cowen 41st Annual Health Care Conference Pre...
NuCana (NCNA) announces interim data from the ongoing three-part study NuTide:302 investigating NUC-3373, a targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.The study is evaluating NUC-3373’s optimal dose and schedule in combina...
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be Favorable EDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc ...
Gainers: Live Ventures (LIVE) +87%.GameStop (GME) +63%.Exela Technologies (XELA) +51%.AMMO (POWW) +41%.Castor Maritime (CTRM) +35%.Acorda Therapeutics (ACOR) +32%.Root (ROOT) +32%.Ondas Holdings (ONDS) +30%.NuCana (NCNA) +26%.Foresight Autonomous (FRSX) +26%.Losers:...
Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutu...
Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a patent for a 3D holograp...
Pharmaceutical Executive Brings a Wealth of Experience to NuCana’s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics EDINBURGH, United Kingdom, Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana p...
Gainers: [[NTN]] +20.7%. [[WDC]] +7.9%. [[NCNA]] +7.4%. [[SPCE]] +5.6%. [[JFIN]] +5.4%.Losers: [[MOHO]] -7.9%. [[COGT]] -6.7%. [[FOUR]] -6.7%. [[EMKR]] -6.6%. [[OBLG]] -6.6%. For further details see: NTN, NCNA, MOHO and EMKR among after-hours movers
Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile Confirmed NuTide:121 Global Phase III Study Recruitment Ongoing EDINBURGH, United Kingdom, Nov. 30, 2020...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...